Company Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Organogenesis Holdings Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
2.49 ^USD	0.00%		+5.96%	-39.12%

May. 02	Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	CI
Feb. 29	Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Number of employees: 862

USD in Million	2022	Weight	2023	Weight	Delta
Advanced Wound Care 93.6 %	422	93.6 %	406	93.6 %	-3.96%
Surgical and Sports Medicine 6.4 %	29	6.4 %	28	6.4 %	-3.61%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	451	100.0 %	433	100.0 %	-3.94%

Managers	Title	Age	Since
Gary Gillheeney CEO	Chief Executive Officer	69	13-12-31
David Francisco DFI	Director of Finance/CFO	59	21-02-15
Patrick Bilbo COO	Chief Operating Officer	63	98-12-31
Lori Freedman ADM	Chief Administrative Officer	57	16-12-31
Mark Collins PRN	Corporate Officer/Principal	-	20-12-31
Robert Cavorsi PRN	Corporate Officer/Principal	-	20-12-31
Kurt Matheson SAM	Sales & Marketing	-	21-05-31
Antonio Montecalvo PRN	Corporate Officer/Principal	59	02-12-31
Brian Grow PRN	Corporate Officer/Principal	48	03-12-31
William R. Kolb SEC	Corporate Secretary	-	-

Members of the board	Title	Age	Since
Glenn Nussdorf BRD	Director/Board Member	70	02-12-31
Alan Ades BRD	Director/Board Member	86	02-12-31
Michael Driscoll BRD	Director/Board Member	63	22-02-14
Gary Gillheeney CEO	Chief Executive Officer	69	13-12-31
Arthur Leibowitz BRD	Director/Board Member	71	17-12-31
Jon Giacomin BRD	Director/Board Member	60	21-05-06
Michele Korfin BRD	Director/Board Member	53	22-05-02
Prathyusha Durabaibu BRD	Director/Board Member	46	21-11-18
David Erani BRD	Director/Board Member	36	20-11-02
Gilberto Quintero BRD	Director/Board Member	59	22-05-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	133,301,013	88,460,749 ( 66.36 %)	728,548 ( 0.5465 %)	66.36 %

Name	Equities	%	Valuation
Alan Ades 11.55 %	15,244,272	11.55 %	43 M $
Glenn Nussdorf 11.34 %	14,963,663	11.34 %	42 M $
Morgan Stanley Investment Management, Inc. 10.14 %	13,377,756	10.14 %	38 M $
Soleus Capital Management LP 6.792 %	8,963,000	6.792 %	25 M $
Organo Pfg LLC 6.274 %	8,279,490	6.274 %	24 M $
Albert Erani 5.762 %	7,604,024	5.762 %	22 M $
Vanguard Fiduciary Trust Co. 4.062 %	5,360,727	4.062 %	15 M $
BlackRock Advisors LLC 3.737 %	4,931,832	3.737 %	14 M $
Organo Investors LLC 2.161 %	2,851,984	2.161 %	8 M $
Acadian Asset Management LLC 1.917 %	2,529,938	1.917 %	7 M $

Organogenesis Holdings, Inc.

85 Dan Road

02021, Canton

+781 575 0775

http://www.organogenesis.com

address Organogenesis Holdings Inc.(ORGO)

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.49 USD

Average target price

4.833 USD

Spread / Average Target

+94.11%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORGANOGENESIS HOLDINGS INC.	-39.12%	330M
MODERNA, INC.	+25.69%	48.09B
LONZA GROUP AG	+46.90%	40.62B
IQVIA HOLDINGS INC.	-3.46%	40.43B
CELLTRION, INC.	-6.20%	28.36B
ICON PUBLIC LIMITED COMPANY	+9.17%	24.89B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.01B
MEDPACE HOLDINGS, INC.	+28.07%	12.09B
BIO-TECHNE CORPORATION	+0.17%	11.88B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.8B

Other Biotechnology & Medical Research